Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
Conditions
Brief summary
There are limited options for treatment of relapse/refractory acute myeloid leukemia (AML). CD123 CAR-T cells may have an attractive and permanent effect on anti-tumor. This study purpose to estimate the safety and efficiency of CD123 CAR-T cells to patients with relapse/refractory AML.
Detailed description
CD123 is expressed on most myeloid leukemia cells so it is a ideal target for CAR-T. Some researches have revealed that CD123 is a marker of leukemia stem cells, which indicates that the eradication of CD123 cells may prevent relapse of leukemia. In this study, investigators will evaluate the safety and efficacy of CAR-T targeting CD123 in patients with Acute Myelocytic Leukemia. The primary goal is safety and efficiency assessment, including adverse events and disease status after treatment.
Interventions
BIOLOGICALCD123 CAR-T cells
CD123 CAR-T cell therapy
Sponsors
Chongqing Precision Biotech Co., Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Signed written informed consent； 2. Diagnose as Relapsed/Refractory AML, and meet one of the following conditions： 1. With persistent disease after at least two lines of therapy； 2. Relapse to the last line of therapy in 6 months，as known as early recurrence; 3. Relapse to the last line of therapy after 6 months, but refractory to this last line of therapy； 4. Relapse more than once. The definition of relapse: Reappearance of blasts in the blood or bone marrow (\>5%) or in any extramedullary site after a CR (the most common are CNS and testicular leukemia). 3. Evidence for cell membrane CD123 expression; 4. KPS\>60; 5. The expect time of survive is above 3 months; 6. Ages: 2 to 75 years; 7. All genders; 8. The patients that diagnosis as high risks, relapse/refractory or inconformity criteria to other therapy； 9. No serious mental disorders; 10. Left ventricular ejection fraction ≥40%; 11. Sufficient hepatic function defined by ALT/AST\<5 x ULN and bilirubin≤34.2μmol/L; 12. Sufficient renal function defined by creatinine clearance \<220μmol/L; 13. Sufficient pulmonary function defined by indoor oxygen saturation≥92%; 14. No other illness may conflict with the protocol (e.g. autoimmune diseases, immune deficiency and organ transplantation； 15. Ability and willingness to adhere to the study visit schedule and all protocol requirements.
Exclusion criteria
1. Previous history of other malignancy; 2. Presence of uncontrolled active infection; 3. Evidence of disorder that need the treatment by glucocorticoids; 4. Active or chronic GVHD； 5. The patients treatment by inhibitor of T cell； 6. Pregnant or breasting-feeding women; 7. Any situation that investigators regard not suitable for attending in this study (e.g. HIV , HCVinfection or intravenous drug addiction) or may affect the data analysis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events that related to treatment | 2 years | Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0). |
| The response rate of CD123 CAR-T treatment in patients with relapse/refractory AML that treatment by CD123 CAR-T cells therapy | 2 years | The response rate of CD123 CAR-T treatment will be recorded and assessed according to the National Comprehensive Cancer Network Guideline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cellular kinetics of CD123 positive cells in Bone marrow | 1 years | In vivo (bone marrow) rate and quantity of CD123 positive cells were determined by means of flow cytometry |
| Duration of Response (DOR) of CD123 CAR-T treatment in patients with refractory/relapsed AML | 2 years | DOR will be assessed from the first assessment of CR or CRi to the first assessment of recurrence or progression of the disease or death from any cause (censored) |
| Cellular kinetics of CD123 CAR-T in Blood | 2 years | In vivo (peripheral blood) rate and quantity of CD123 CAR-T cells were determined by means of flow cytometry and qPCR |
| Overall survival(OS) of CD123 CAR-T treatment in patients with refractory/relapsed AML | 2 years | OS will be assessed from the first CAR-T cell infusion to death from any cause (censored) |
| Progress-free survival(PFS) of CD123 CAR-T treatment in patients with refractory/relapsed AML | 2 years | PFS will be assessed from the first CAR-T cell infusion to death from any cause or the first assessment of progression (censored) |
| Cellular kinetics of CD123 CAR-T in Bone marrow | 2 years | In vivo (bone marrow) rate and quantity of CD123 CAR-T cells were determined by means of flow cytometry and qPCR |
Countries
China
Contacts
Primary ContactZhi Yang, PhD
Outcome results
None listed